The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo
Open accessAbstract
Somatic Addition of Sex Combs Like 1 (ASXL1) mutations occur in 10–30% of patients with myeloid malignancies, most commonly in myelodysplastic syndromes (MDSs), and are associated with adverse outcome. Germline ASXL1 mutations occur in patients with Bohring-Opitz syndrome. Here, we show that constitutive loss of Asxl1 results in developmental abnormalities, including anophthalmia, microcephaly, cleft palates, and mandibular malformations. In contrast, hematopoietic-specific deletion of Asxl1 results in progressive, multilineage cytopenias and dysplasia in the context of increased numbers of hematopoietic stem/progenitor cells, characteristic features of human MDS. Serial transplantation of Asxl1-null hematopoietic cells results in a lethal myeloid disorder at a shorter latency than primary Asxl1 knockout (KO) mice. Asxl1 deletion reduces hematopoietic stem cell self-renewal, which is restored by concomitant deletion of Tet2, a gene commonly co-mutated with ASXL1 in MDS patients. Moreover, compound Asxl1/Tet2 deletion results in an MDS phenotype with hastened death compared with single-gene KO mice. Asxl1 loss results in a global reduction of H3K27 trimethylation and dysregulated expression of known regulators of hematopoiesis. RNA-Seq/ChIP-Seq analyses of Asxl1 in hematopoietic cells identify a subset of differentially expressed genes as direct targets of Asxl1. These findings underscore the importance of Asxl1 in Polycomb group function, development, and hematopoiesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
Patel, J. P., Gönen, M., Figueroa, M. E., Fernandez, H., Sun, Z., Racevskis, J., Van Vlierberghe, P., Dolgalev, I., Thomas, S., Aminova, O., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112304 · Cited by 1,946
Self-citation"Stemness": Transcriptional Profiling of Embryonic and Adult Stem Cells
Ramalho-Santos, M., Yoon, S., Matsuzaki, Y., Mulligan, R. C., & Melton, D. A. (2002) · Science · doi:10.1126/science.1072530 · Cited by 1,709
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Self-citationJacobs, J. J. L., Kieboom, K., Marino, S., DePinho, R. A., & van Lohuizen, M. (1999) · Nature · doi:10.1038/16476 · Cited by 1,580
A Stem Cell Molecular Signature
Ivanova, N. B., Dimos, J. T., Schaniel, C., Hackney, J. A., Moore, K. A., & Lemischka, I. R. (2002) · Science · doi:10.1126/science.1073823 · Cited by 1,542
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation
Moran-Crusio, K., Reavie, L., Shih, A., Abdel-Wahab, O., Ndiaye-Lobry, D., Lobry, C., Figueroa, M. E., Vasanthakumar, A., Patel, J., Zhao, X., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.001 · Cited by 1,339
Self-citationEfficient in vivo manipulation of mouse genomic sequences at the zygote stage.
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W., & Westphal, H. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5860 · Cited by 1,125
Quivoron, C., Couronné, L., Della Valle, V., Lopez, C. K., Plo, I., Wagner-Ballon, O., Do Cruzeiro, M., Delhommeau, F., Arnulf, B., Stern, M.-H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.06.003 · Cited by 924
Bracken, A. P., Kleine-Kohlbrecher, D., Dietrich, N., Pasini, D., Gargiulo, G., Beekman, C., Theilgaard-Mönch, K., Minucci, S., Porse, B. T., Marine, J.-C., et al. (2007) · Genes & Development · doi:10.1101/gad.415507 · Cited by 850
Mutations and prognosis in primary myelofibrosis
Vannucchi, A. M., Lasho, T. L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., et al. (2013) · Leukemia · doi:10.1038/leu.2013.119 · Cited by 770
Li, Z., Cai, X., Cai, C.-L., Wang, J., Zhang, W., Petersen, B. E., Yang, F.-C., & Xu, M. (2011) · Blood · doi:10.1182/blood-2010-12-325241 · Cited by 671
Ko, M., Bandukwala, H. S., An, J., Lamperti, E. D., Thompson, E. C., Hastie, R., Tsangaratou, A., Rajewsky, K., Koralov, S. B., & Rao, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112317108 · Cited by 616
The role of mutations in epigenetic regulators in myeloid malignancies
Shih, A. H., Abdel-Wahab, O., Patel, J. P., & Levine, R. L. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3343 · Cited by 611
Self-citationASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H., Pandey, S., Patel, J. P., Chung, Y. R., Koche, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.032 · Cited by 599
Self-citationClassification of pediatric acute lymphoblastic leukemia by gene expression profiling
Ross, M. E., Zhou, X., Song, G., Shurtleff, S. A., Girtman, K., Williams, W. K., Liu, H.-C., Mahfouz, R., Raimondi, S. C., Lenny, N., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0338 · Cited by 590
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 564
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
Itzykson, R., Kosmider, O., Renneville, A., Gelsi-Boyer, V., Meggendorfer, M., Morabito, M., Berthon, C., Adès, L., Fenaux, P., Beyne-Rauzy, O., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3314 · Cited by 545
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1.
Rosenbauer, F., Wagner, K., Kutok, J. L., Iwasaki, H., Le Beau, M. M., Okuno, Y., Akashi, K., Fiering, S., & Tenen, D. G. (2004) · Nature Genetics · doi:10.1038/ng1361 · Cited by 506
Bejar, R., Stevenson, K. E., Caughey, B. A., Abdel-Wahab, O., Steensma, D. P., Galili, N., Raza, A., Kantarjian, H., Levine, R. L., Neuberg, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7379 · Cited by 441
Self-citationLoss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Dey, A., Seshasayee, D., Noubade, R., French, D. M., Liu, J., Chaurushiya, M. S., Kirkpatrick, D. S., Pham, V. C., Lill, J. R., Bakalarski, C. E., et al. (2012) · Science · doi:10.1126/science.1221711 · Cited by 412
Self-citationA novel tumour-suppressor function for the Notch pathway in myeloid leukaemia
Klinakis, A., Lobry, C., Abdel-Wahab, O., Oh, P., Haeno, H., Buonamici, S., van De Walle, I., Cathelin, S., Trimarchi, T., Araldi, E., et al. (2011) · Nature · doi:10.1038/nature09999 · Cited by 382
Self-citationJankowska, A. M., Makishima, H., Tiu, R. V., Szpurka, H., Huang, Y., Traina, F., Visconte, V., Sugimoto, Y., Prince, C., O'Keefe, C., et al. (2011) · Blood · doi:10.1182/blood-2010-10-311019 · Cited by 330
Mizuki, M., Schwäble, J., Steur, C., Choudhary, C., Agrawal, S., Sargin, B., Steffen, B., Matsumura, I., Kanakura, Y., Böhmer, F. D., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1677 · Cited by 298
Germline deletion of the miR-17∼92 cluster causes skeletal and growth defects in humans
de Pontual, L., Yao, E., Callier, P., Faivre, L., Drouin, V., Cariou, S., Van Haeringen, A., Geneviève, D., Goldenberg, A., Oufadem, M., et al. (2011) · Nature Genetics · doi:10.1038/ng.915 · Cited by 295
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes
Pang, W. W., Pluvinage, J. V., Price, E. A., Sridhar, K., Arber, D. A., Greenberg, P. L., Schrier, S. L., Park, C. Y., & Weissman, I. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222861110 · Cited by 277 · cited 5×
“, 2012), and an increase in the frequency and absolute number of HSPCs in the setting of decreased mature circulating cells with a concomitant increase in apoptosis of HSPCs in MDS patients (Sawada et al., 1993, 1995; Pang et al., 2013).”
BackgroundSelf-citationPrognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Thol, F., Friesen, I., Damm, F., Yun, H., Weissinger, E. M., Krauter, J., Wagner, K., Chaturvedi, A., Sharma, A., Wichmann, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.4938 · Cited by 277
Metzeler, K. H., Becker, H., Maharry, K., Radmacher, M. D., Kohlschmidt, J., Mrózek, K., Nicolet, D., Whitman, S. P., Wu, Y.-Z., Schwind, S., et al. (2011) · Blood · doi:10.1182/blood-2011-08-368225 · Cited by 275
De novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome
Hoischen, A., van Bon, B. W. M., Rodríguez-Santiago, B., Gilissen, C., Vissers, L. E. L. M., de Vries, P., Janssen, I., van Lier, B., Hastings, R., Smithson, S. F., et al. (2011) · Nature Genetics · doi:10.1038/ng.868 · Cited by 271
Boultwood, J., Perry, J., Pellagatti, A., Fernandez-Mercado, M., Fernandez-Santamaria, C., Calasanz, M. J., Larrayoz, M. J., Garcia-Delgado, M., Giagounidis, A., Malcovati, L., et al. (2010) · Leukemia · doi:10.1038/leu.2010.20 · Cited by 264
Persistent Malignant Stem Cells in del(5q) Myelodysplasia in Remission
Tehranchi, R., Woll, P. S., Anderson, K., Buza-Vidas, N., Mizukami, T., Mead, A. J., Åstrand-Grundström, I., Strömbeck, B., Horvat, A., Ferry, H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0912228 · Cited by 253
Vangala, R. K., Heiss-Neumann, M. S., Rangatia, J. S., Singh, S. M., Schoch, C., Tenen, D. G., Hiddemann, W., & Behre, G. (2003) · Blood · doi:10.1182/blood-2002-04-1288 · Cited by 245
Heterozygous PU.1 mutations are associated with acute myeloid leukemia
Mueller, B. U., Pabst, T., Osato, M., Asou, N., Johansen, L. M., Minden, M. D., Behre, G., Hiddemann, W., Ito, Y., & Tenen, D. G. (2002) · Blood · doi:10.1182/blood.v100.3.998 · Cited by 243
Stadtfeld, M., & Graf, T. (2005) · Development · doi:10.1242/dev.01558 · Cited by 242
Nilsson, L., Åstrand-Grundström, I., Arvidsson, I., Jacobsson, B., Hellström-Lindberg, E., Hast, R., & Jacobsen, S. E. W. (2000) · Blood · doi:10.1182/blood.v96.6.2012 · Cited by 241
Will, B., Zhou, L., Vogler, T. O., Ben-Neriah, S., Schinke, C., Tamari, R., Yu, Y., Bhagat, T. D., Bhattacharyya, S., Barreyro, L., et al. (2012) · Blood · doi:10.1182/blood-2011-12-399683 · Cited by 238
Lin, Y.-W., Slape, C., Zhang, Z., & Aplan, P. D. (2005) · Blood · doi:10.1182/blood-2004-12-4794 · Cited by 230
Hidalgo, I., Herrera-Merchan, A., Ligos, J. M., Carramolino, L., Nuñez, J., Martinez, F., Dominguez, O., Torres, M., & Gonzalez, S. (2012) · Cell Stem Cell · doi:10.1016/j.stem.2012.08.001 · Cited by 222 · cited 1×
“The p16INK4a locus is a known PRC2 target (Jacobs et al., 1999; Bracken et al., 2007; Hidalgo et al., 2012; Tanaka et al., 2012), and in vitro loss of Asxl1 has been linked to defective Polycomb repression and reduced H3K27 methylation (Abdel-Wahab et al., 2012).”
BackgroundEzh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia
Tanaka, S., Miyagi, S., Sashida, G., Chiba, T., Yuan, J., Mochizuki-Kashio, M., Suzuki, Y., Sugano, S., Nakaseko, C., Yokote, K., et al. (2012) · Blood · doi:10.1182/blood-2011-11-394932 · Cited by 186
Essential role of Jun family transcription factors in PU.1 knockdown–induced leukemic stem cells
Steidl, U., Rosenbauer, F., Verhaak, R. G. W., Gu, X., Ebralidze, A., Otu, H. H., Klippel, S., Steidl, C., Bruns, I., Costa, D. B., et al. (2006) · Nature Genetics · doi:10.1038/ng1898 · Cited by 184
NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia.
Raza-Egilmez, S. Z., Jani-Sait, S., Grossi, M., Higgins, M. J., Shows, T. B., & Aplan, P. D. (1998) · PubMed · Cited by 184
Polycomb Group Gene rae28 Is Required for Sustaining Activity of Hematopoietic Stem Cells
Ohta, H., Sawada, A., Kim, J. Y., Tokimasa, S., Nishiguchi, S., Humphries, R. K., Hara, J., & Takihara, Y. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011911 · Cited by 182
Mullighan, C. G., Kennedy, A., Zhou, X., Radtke, I., Phillips, L. A., Shurtleff, S. A., & Downing, J. R. (2007) · Leukemia · doi:10.1038/sj.leu.2404808 · Cited by 180
Fisher, C. L., Pineault, N., Brookes, C., Helgason, C. D., Ohta, H., Bodner, C., Hess, J. L., Humphries, R. K., & Brock, H. W. (2009) · Blood · doi:10.1182/blood-2009-07-230698 · Cited by 164
Nilsson, L., Edén, P., Olsson, E., Månsson, R., Åstrand‐Grundström, I., Strömbeck, B., Theilgaard‐Mönch, K., Anderson, K., Hast, R., Hellström‐Lindberg, E., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079368 · Cited by 115
Fisher, C. L., Lee, I., Bloyer, S., Bozza, S., Chevalier, J. R., Dahl, A., Bodner, C., Helgason, C. D., Hess, J. L., Humphries, R. K., et al. (2009) · Developmental Biology · doi:10.1016/j.ydbio.2009.10.004 · Cited by 86
Role of Transcription Factors C/EBPa and PU.1 in Normal Hematopoiesis and Leukemia
Koschmieder, S., Rosenbauer, F., Steidl, U., Owens, B. M., & Tenen, D. G. (2005) · International Journal of Hematology · doi:10.1532/ijh97.05051 · Cited by 72
Haferlach, C., Bacher, U., Schnittger, S., Alpermann, T., Zenger, M., Kern, W., & Haferlach, T. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.21918 · Cited by 59
The diverse role of the ETS family of transcription factors in cancer.
Gilliland, D. G. (2001) · PubMed · Cited by 44
Two novel patients with Bohring–Opitz syndrome caused by de novo ASXL1 mutations
Magini, P., Monica, M. D., Uzielli, M. L. G., Mongelli, P., Scarselli, G., Gambineri, E., Scarano, G., & Seri, M. (2012) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.35265 · Cited by 43
Cited by
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
Role of TET enzymes in DNA methylation, development, and cancer
Rasmussen, K. D., & Helin, K. (2016) · Genes & Development · doi:10.1101/gad.276568.115 · Cited by 1,040
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia
Yoshizato, T., Dumitriu, B., Hosokawa, K., Makishima, H., Yoshida, K., Townsley, D., Sato-Otsubo, A., Sato, Y., Liu, D., Suzuki, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414799 · Cited by 646
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
Vainchenker, W., & Kralovics, R. (2017) · Blood · doi:10.1182/blood-2016-10-695940 · Cited by 616
Medyouf, H., Mossner, M., Jann, J.-C., Nolte, F., Raffel, S., Herrmann, C., Lier, A., Eisen, C., Nowak, V., Zens, B., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.02.014 · Cited by 388
Metadata
- Authors
- Abdel-Wahab, O., Gao, J., Adli, M., Dey, A., Trimarchi, T., Chung, Y. R., Kuscu, C., Hricik, T., Ndiaye-Lobry, D., LaFave, L. M., Koche, R., Shih, A. H., Guryanova, O. A., Kim, E., Li, S., Pandey, S., Shin, J. Y., Telis, L., Liu, J., Bhatt, P. K., Monette, S., Zhao, X., Mason, C. E., Park, C. Y., Bernstein, B. E., Aifantis, I., & Levine, R. L.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-11-11
- Volume
- 210
- Issue
- 12
- Pages
- 2641-2659
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2115551519
- Cited by
- 322
- References
- 51
- FWCI
- 18.56
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.